Using chemically modified insulin in a new test for type 1 diabetes
Scientific title: Oxidative post-translationally modified insulin as neoepitope in type 1 diabetes: staging, pathogenesis and therapeutic utility
Principal Investigator: Dr Ahuva Nissim
Institution: Queen Mary University of London
Project duration: 01/10/2017 – 30/09/2020
Objective: Dr Nissim is developing a technique to measure the presence of immune system proteins formed against a chemically-modified version of insulin found on the beta cells and in the blood of people living with type 1 diabetes. The technique will also measure how much of the chemically modified insulin is present in the blood. The technique would form the basis of a new test that could be used to help predict, diagnose, stage and treat type 1 diabetes.
If successful, the new test could be added to standard blood tests when checking for type 1 diabetes-associated proteins. This additional test would be particularly useful to identify people at risk of type 1 who do not test positive for any of the four key immune system proteins associated with type 1.
Understanding how the chemically-modified insulin plays a role in early type 1 progression could also help the development of future approaches intended to prevent the immune attack on the beta cells as a result of the presence of the chemically-modified insulin.
Categories: Prevent, predict, stage